stay 1 day. Median number of nodes resected was 19 (range, 8-93); 3 patients (30%) had positive nodes. Four patients had minor (Clavien 1-2) complications. At median follow-up of 5 months (1-24), median PSA reduction was 82%. Median time-to-nadir PSA was 3 months. Continence and potency status remained unchanged from baseline.
INTRODUCTION AND OBJECTIVES: Focal therapy (FT) for prostate cancer (PCa) presents non-negligible rates of disease recurrence. We aim to assess the outcomes of redoing FT (s-FT) after FT failure as an alternative to radical salvage procedures METHODS: From 2010 to 2018, 37 patients underwent s-FT and 28 patients salvage robotic radical prostatectomy (s-RRP) after focal high-intensity focused ultrasound, cryotherapy or vascular targeted photodynamic therapy. Patients with less than 3 months of follow-up or whole-gland energy salvage treatment were excluded. We also excluded Gleason score (GS) ! 7 (4þ3) and PSA ! 20ng/ml patients aiming to reduce selection bias. Functional outcomes were reported at 3 and 12 months. Urinary incontinence was defined as ! 1 daily pads. Complications were registered according to Clavien-Dindo classification. Failure was defined as positive biopsy GS ! 7 in s-FT group, PSA ! 0.2ng/ml in s-RRP group, need of retreatment, metastasis or PCa-specific death RESULTS: Forty-eight (s-FT: 30 and s-RRP:18) patients were enrolled in the analysis with a median follow-up of 36mo (interquartile range [IQR] 17-53) and 22mo (IQR 6-37); p[0.06 in s-FT and s-RRP groups, respectively. There were no significant differences between the groups regarding age, prostate-specific antigen (PSA), sexual activity or urinary function at baseline. In s-FT and s-RRP groups, GS 6 (3þ3) was found in 65.5% and 27.8% and GS 7 (3þ4) in 34.5% and 72.2% of patients, respectively (p[0.02). There was no significant difference in complications grade 2 or greater between the groups. Only a patient in s-RRP group presented a grade 3 complication. Failure-free survival in s-FT and s-RRP groups were 96.4% (95% CI 3.5-77.2) and 79.5% (95% CI 10.7-48.3) at 1-yr and 54.2% (95% CI 10.9-31.2) and 47.7% (95% CI 13.9-20.2) at 3-yr, respectively (p[0.27). Only one patient presented PCa-metastasis in s-RRP group. No PCa-specific death was seen in this study. Median ICSmale score was 1 (IQR 0-2) and 9 (IQR 3-12), p<0.001 and median IIEF-5 score was 9 (IQR 3-18) and 1 (IQR 1-9), p[0.007, at 3 months after s-FT and s-RRP, respectively. Enough erection for sexual activity was found in 15 (57.7%) and 0 patients at 3mo, and 13 (72.2%) and 1 (7.1%) at 12mo, p<0.001, respectively. While no patient presented urinary incontinence in s-FT group, it was present in 12 patients (66.6%, p<0.001) at 3mo and in 4 (26.7%, p[0.07) . Focal therapies for prostate cancer are increasingly being explored and new treatments for salvage patients are being studied. Our objective is to investigate the efficacy of using MRguided laser focal therapy for MR-visible prostate cancer utilizing a transrectal approach for laser applicator placement and therapy delivery in an outpatient setting. Lasers have been used for soft tissue necrotization for decades [2] . A commercially available MRguided biopsy system allows insertion of a laser fiber into biopsyproven cancer for ablation of MR-visible tumor.
METHODS: All MRI-guided therapy was delivered using a 1.5 Tesla Philips Achieva XR system (Philips Healthcare, Best, The Netherlands) for both image acquisition and real-time thermometry. DynaCAD and DynaLOC (Invivo, Orlando, FL, USA) software were used for image analysis and laser fiber placement planning. Laser focal therapy was delivered using a Visualase (Medtronic, Minneapolis, MN, USA) 15W, 980 nm diode laser. Visualase (salinecooled) fibers or Tranberg Clinical Laserthermia (CLS Americas, Framingham, MA, USA) (non-cooled) fibers were introduced transrectally. MR imaging and MR-thermometry were used to monitor energy deposition and coagulation necrosis.
RESULTS: Under IRB-approved, HIPAA-compliant protocol, 130 men and 198 cancer foci were treated. Total procedure time was between 1.5 and four hours MRI volume of coagulation necrosis ranged from 0.6 to 38 cc (mean 7.2 cc, median 6.2 cc). No serious adverse events or morbidity were reported. Of the 131 lesions (in 94 men) for which we had 6 mo. biopsies of the treatment regions available, 27/131 of lesions (21%) in 20/95 of men (21%) were positive and clinically significant*, while 83/131 of lesions (63%) in 61/95 of men (65%) were negative. We observed a 40% decrease in mean PSA at 12 months post therapy and no statistically significant change in IPSS and SHIM scores.
*Excludes Gleason score 3þ3[6 CONCLUSIONS: Our data indicate that outpatient, transrectally-delivered MRI-guided laser focal therapy for prostate cancer is both safe and feasible. The precision and controllability achieved under MRI-guidance may have favorable results for cost effectiveness and quality of life without eliminating the possibility of whole-gland treatment in the patient's future. We will continue to follow these men for twenty years as part of an IRB-approved clinical trial (NCT#02243033) [3] .
Source of Funding: None
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